TP53 and ovarian carcinoma: The second most significant co-mutation, TP53:TTN-AS1, involves a non-coding gene, and it was mined from ICGC’s ovarian cancer Australia cohort (OV-AU) (HR = 2.16, 95% CI 1.22–3.85).